RGT-490 Clinical Trials (2026): 1 Studies for Advanced Breast Cancer & Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 RGT-490 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Breast Cancer & Breast Cancer) and 63 total planned enrollment. 1 RGT-490 clinical trial is actively recruiting at 4 U.S. sites across 3 states. Most recent activity: NCT07524322 (Oct 2028).
Where to Participate: All RGT-490 Trial Sites in the U.S. (4 sites across 3 states)
Every actively recruiting RGT-490trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | START Los Angeles | Los Angeles90025 | NCT07524322 | Map |
| TX | NEXT Houston | Houston77054 | NCT07524322 | Map |
| TX | NEXT San Antonio | San Antonio78229 | NCT07524322 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT07524322 | Map |
RGT-490 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting RGT-490 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | P1 | Breast Cancer | 63 | Jun 2026 |
All RGT-490 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07524322 | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors | P1 | recruiting | 63 | Regor Pharmaceuticals Inc. | Jun 2026 |
RGT-490 clinical trials: frequently asked questions
- How many RGT-490 clinical trials are there?
- 1 RGT-490 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are RGT-490 clinical trials recruiting in 2026?
- Yes — 1 RGT-490 trial is actively recruiting in 2026, with 4 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is RGT-490 being studied for?
- RGT-490 is being studied for Advanced Breast Cancer, Breast Cancer, Cervical Cancer, Endometrial Cancer, HER2- Negative Breast Cancer and 4 more. The trials are grouped by indication on this page.
- What phase is RGT-490 in?
- RGT-490 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors RGT-490 clinical trials?
- The lead sponsor across the most RGT-490 trials is Regor Pharmaceuticals Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming RGT-490as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: